Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/29/2871258/29489/en/AIM-ImmunoTech-Announces-First-Dose-Level-is-Generally-Well-Tolerated-in-Phase-1b-2-Study-of-Ampligen-and-Imfinzi-as-a-Combination-Therapy-for-Late-Stage-Pancreatic-Cancer.html
https://www.globenewswire.com/news-release/2024/04/25/2869669/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html
https://www.globenewswire.com/news-release/2024/04/18/2865414/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html
https://www.globenewswire.com/news-release/2024/04/15/2862795/29489/en/AIM-ImmunoTech-Announces-Charles-Lapp-MD-as-a-Consulting-Medical-Officer-for-its-ME-CFS-and-Long-COVID-Programs.html
https://www.globenewswire.com/news-release/2024/04/11/2861666/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html
https://www.globenewswire.com/news-release/2024/04/10/2860723/29489/en/AIM-ImmunoTech-Announces-Positive-Top-Line-Protocol-Planned-Interim-Report-Data-from-the-Study-of-Ampligen-Combined-with-Pembrolizumab-for-the-Treatment-of-Recurrent-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/04/02/2855844/29489/en/AIM-ImmunoTech-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/03/28/2853964/29489/en/AIM-ImmunoTech-to-Present-at-the-MedInvest-Biotech-Pharma-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/03/26/2852433/29489/en/AIM-ImmunoTech-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-April-2-2024-and-Host-Conference-Call-and-Webcast.html
https://www.globenewswire.com/news-release/2024/03/22/2850954/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html